QDEL, US2197981051

QuidelOrtho stock gained 3.54 percent on October 6

Published on 10/07/2026 at 01:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

QuidelOrtho stock reported USD 630.9 million in second-quarter revenue on August 6, 2026. Six analysts assign a Reduce consensus and USD 13.62 average target.

QDEL, US2197981051, Illustration mit AI erstellt.

QuidelOrtho stock (ISIN US2197981051) gained 3.54 percent to USD 12.57 on Nasdaq on October 6, 2026, with 3,218,409 shares traded. The move puts the diagnostics company back above its USD 12.00 price level, while the latest earnings picture remains mixed.

Revenue grows while losses persist

According to StockTitan, QuidelOrtho reported second-quarter 2026 revenue of USD 630.9 million for the period ended June 28, 2026, up 2.8 percent from the prior-year quarter. The same filing summary lists a GAAP net loss of USD 92.9 million, or USD 1.36 per diluted share.

The quarter also delivered adjusted EPS of USD 0.13 against a consensus loss of USD 0.05, a USD 0.18 positive variance. That comparison matters because the revenue increase did not translate into GAAP profitability, leaving operating execution and cash generation as the next tests for the recovery story.

Debt terms frame the recovery

QuidelOrtho amended its credit agreement on September 23, 2026. The SEC filing describes a USD 1.15 billion senior secured term loan A facility, a USD 100.0 million delayed-draw facility, a USD 1.45 billion term loan B and a USD 700.0 million revolving credit facility.

The amendment resets financial covenants through September 30, 2029, including a maximum consolidated leverage ratio of 5.50 to 1.00 through July 2, 2028 and a minimum interest coverage ratio of 2.25 to 1.00 over the same initial period. For investors, the financing terms make balance-sheet progress as important as the revenue trajectory.

Analysts see limited upside

According to MarketBeat on October 5, 2026, six analysts hold a consensus Reduce rating, split between three Holds and three Sells, with an average price target of USD 13.62. The target lies 8.36 percent above the USD 12.57 Nasdaq price.

MarketBeat also reports that QuidelOrtho reduced its full-year 2026 adjusted EPS guidance to USD 0.65-0.90. The combination of a quarterly revenue beat, continuing GAAP losses and tighter financing conditions explains why the stock can rally sharply while analyst sentiment remains cautious.

Nasdaq price and market value

QuidelOrtho was last at USD 12.57 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. Its market capitalization was USD 857.2 million, with a 52-week range of USD 9.92 to USD 35.58.